 | Up a level |
2022
Schambeck, L., Olliges, E., Herrmann-Lingen, C., Ronel, J., Petrowski, K., Marten-Mittag, B., Schmidt, R., Braun, S., Albus, C., Deter, H., De Zwaan, M., Michal, M., Soellner, W., Weber, C., Juenger, J., Fritzsche, K. and Ladwig, K. (2022). Socio-demographic and psychometric aspects and baseline inflammatory markers in depressed patients with coronary artery disease - Add-on analysis of the multicentre SPIRR-CAD trial. J. Psychosomat. Res., 157. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1879-1360
2020
Berthold, F., Faldum, A., Ernst, A., Boos, J., Dilloo, D., Eggert, A., Fischer, M., Fruehwald, M., Henze, G., Klingebiel, T., Kratz, C., Kremens, B., Krug, B., Leuschner, I, Schmidt, M., Schmidt, R., Schumacher-Kuckelkorn, R., von Schweinitz, D., Schilling, F. H., Theissen, J., Volland, R., Hero, B. and Simon, T. (2020). Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Ann. Oncol., 31 (3). S. 422 - 430. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2015
Rosswog, C., Schmidt, R., Oberthuer, A., Juraeva, D., Brors, B., Westermann, F., Berthold, F., Simon, T., Hero, B., Faldum, A. and Fischer, M. (2015). DEVELOPMENT OF A SCORING SYSTEM BASED ON A PROGNOSTIC INDEX FOR RISK ASSESSMENT OF PATIENTS WITH NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S178 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017
2014
Fischer, M., Oberthuer, A., Juraeva, D., Schmidt, R., Faldum, A., Berthold, F., Westermann, F., Brors, B., Simon, T. and Hero, B. (2014). REVISED RISK ESTIMATION AND TREATMENT STRATIFICATION OF LOW- AND INTERMEDIATE-RISK NEUROBLASTOMA PATIENTS BY INTEGRATING CLINICAL AND MOLECULAR PROGNOSTIC MARKERS. Pediatr. Blood Cancer, 61. S. S119 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017